[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unresectable-hepatocellular-carcinoma-hcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unresectable-hepatocellular-carcinoma-hcc":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,67,92,126,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638397","multimodal-thermal-therapy-with-targeted-and-immunotherapy-for-untreated-unresectable-hcc-100638397",false,"NCT07596134","Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC","Multimodal Thermal Therapy With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone for Systemically Untreated Unresectable (HCC): a Prospective, Multicenter, Open-label, Randomized Controlled Trial.","HLP1-1331","Inclusion Criteria:\n\n* • Age 18-80, regardless of gender;\n\n  * Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;\n  * No prior systemic immunotherapy, chemotherapy, targeted therapy, or other systemic drug treatments for HCC;\n  * Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;\n  * Child-Pugh score ≤7;\n  * ECOG-PS score of 0-1.\n\nExclusion Criteria:\n\n* • Invasion of the main portal vein;\n\n  * Diffuse hepatocellular carcinoma;\n  * Patients with a history or current diagnosis of brain metastases whose symptoms are not fully controlled (i.e., persistent or worsening symptoms, or requiring adjustments to symptomatic treatment to maintain symptom relief);\n  * Extensive distant metastasis confirmed by imaging (e.g., chest\u002Fabdominal CT\u002FMRI, whole-body bone scan, PET-CT, etc.), including but not limited to diffuse lung metastasis, multiple bone metastases, extensive abdominal\u002Fperitoneal metastasis, or other multi-organ metastases, where the investigator assesses that the extent of metastasis may compromise the safe administration of study treatment or affect efficacy and safety evaluations;\n  * Prior local therapy with the last treatment administered less than 4 weeks before enrollment;\n  * Involvement of major blood vessels such as the hepatic vein or inferior vena cava;\n  * Uncontrolled active infection;\n  * Renal dysfunction with serum creatinine \\>176.8 μmol\u002FL or creatinine clearance \\\u003C30 mL\u002Fmin;\n  * Uncorrectable coagulation abnormalities: platelets \\\u003C50×10⁹\u002FL, prothrombin time \\>18 seconds, prothrombin activity \\\u003C40%, and uncorrectable;\n  * History of esophageal or gastric variceal bleeding without effective treatment via endoscopy, intervention, or surgery;\n  * Patients with active psychiatric disorders;\n  * Patients receiving or requiring systemic glucocorticoids (e.g., prednisone, dexamethasone) at a dose ≥10 mg\u002Fday (prednisone equivalent) or other immunosuppressive drugs (e.g., cyclosporine, tacrolimus, methotrexate) within 14 days prior to enrollment; topical, inhaled, or ophthalmic glucocorticoid use that does not affect systemic immune function may be allowed at the investigator's discretion;\n  * History or current diagnosis of malignancies other than the target tumor in this study (excluding cured low-grade malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ). For low-grade malignancies, eligibility will be determined by the investigator;\n  * Pregnant or breastfeeding women, or women of childbearing potential planning pregnancy during the study or within 3 months after treatment completion;\n  * Expected survival \\\u003C3 months;\n  * Patients deemed unsuitable for participation by the investigator.","ALL","18 Years","80 Years",{"count":21,"type":22},166,"ESTIMATED","INTERVENTIONAL",[25],"NA","Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)",[28],"Unresectable Hepatocellular Carcinoma (HCC)",[30],"HCC","NOT_YET_RECRUITING","2026-05-19",{"date":34,"type":35},"2026-05-22","ACTUAL",{"date":37,"type":22},"2026-05-25",{"date":39,"type":22},"2029-05-25",{"name":41,"class":42},"Zhejiang University","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100624374","comparison-of-response-between-combination-of-transarterial-chemoembolization-and-lenvatinib-therapy-versus-lenvatinib-monotherapy-in-patients-with-unresectable-hepatocellular-carcinoma-100624374","NCT07408804","Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years,\n2. Hepatocellular carcinoma, confirmed by dynamic CT scan \u002F MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,\n3. At least one measurable lesion based on mRECIST criteria,\n4. ECOG performance status 0-2,\n\nExclusion Criteria:\n\n1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,\n2. Hepatocellular carcinoma with main trunk portal vein thrombosis,\n3. Child Turcotte Pugh Score 10 ( C) or more,\n4. ALBI grade 3,\n5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,\n6. Known allergy or intolerance to lenvatinib .","75 Years",{"count":52,"type":22},40,[25],"The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.",[28],"RECRUITING","2026-02-06",{"date":59,"type":35},"2026-02-13",{"date":61,"type":35},"2025-04-08",{"date":63,"type":22},"2026-09-30",{"name":65,"class":42},"Bangladesh Medical University",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100623069","phase-1-mdn-001-injection-for-the-treatment-of-unresectable-primary-hepatocellular-carcinoma-100623069","NCT07391839","MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.","A Multicenter, Open-label, Single-Arm Phase I\u002FII Clinical Study to Evaluate the Safety and Efficacy of a Single Dose of MDN-001 Injection in Patients With Unresectable Primary Hepatocellular Carcinoma (HCC).","Inclusion Criteria:\n\n* Volunteer to join this study and sign the informed consent form.\n* Age: 18\\~80 years old (inclusive), regardless of gender.\n* Clinically diagnosed hepatocellular carcinoma or pathologically diagnosed hepatocellular carcinoma.\n* ECOG performance status of 1 or less\n* Child-Pugh score A or better B (≤7).\n* Patients who are assessed by researchers as currently unacceptable for surgical resection or ablation, or who refuse to undergo surgical resection or ablation.\n* According to mRECIST standard, in contrast-enhanced MRI or CT images, there must be at least one measurable liver target lesion with the longest diameter ≥1 cm. If there are multiple target lesions, the researcher will choose them.\n* According to the researcher's evaluation, the expected survival time is ≥3 months.\n* There is no extrahepatic metastasis, and there are no other malignant tumors besides liver cancer.\n* The main organs function normally and meet the following requirements: blood routine: no blood transfusion or colony stimulating factor (G-CSF) treatment within 14 days before signing the informed consent form, and hemoglobin ≥ 80g\u002FL; Platelet count \\> 50× 109\u002FL; Neutrophil count (ANC) ≥ 1.5× 109\u002FL. Liver function: serum total bilirubin (TBIL)≤2 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤5.0 times ULN；; Alkaline phosphatase (ALP)≤2.5 times ULN；; Albumin \\> 30 g\u002FL. Renal function: creatinine (Cr)≤1.5 times ULN；; Creatinine clearance rate ≥50 mL\u002Fmin (calculated according to Cockcroft-Gault formula). Coagulation function: INR, PT and APTT)≤1.5 times ULN. If the subjects take warfarin or heparin for anticoagulant therapy, it is necessary to ensure that they meet the requirements of the protocol when they stop taking the drug or not. Cardiovascular function: echocardiography: LVEF (left ventricular ejection fraction) ≥50%.\n* According to the standard of CTCAE5.0, all the adverse events of previous systemic anti-tumor therapy were restored to baseline or ≤1 grade \\[except: the neuropathy induced by previous anti-tumor therapy was stable (≤2 grade); Hair loss, fatigue, etc., which are judged by the researchers based on the actual clinical situation, cannot be restored to ≤1 level and will be in a stable state for a long time; Stable hypothyroidism after hormone replacement therapy\\].\n* Women and men of childbearing age must agree to take strict and effective contraceptive measures after signing informed consent, during the study period and within 6 months after the end of the experiment; Men are forbidden to donate sperm during this period, and the pregnancy test results of female subjects of childbearing age during the screening period and within 24 hours before administration must be negative.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not allowed to participate in this study:\n\n* Severe liver dysfunction: including severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome.\n* Patients who are suitable for surgical resection or ablation after evaluation by researchers: 1) patients who are suitable for surgical resection include but are not limited to the following situations: a) patients with good liver reserve function in CNLC Ia\\~IIa stage; B) If the tumor is confined to the same hepatic segment or ipsilateral hemihepatis, after MDT discussion, the patients with CNLC IIb stage who may get better effect by surgical resection than other treatments; 2) Suitable for ablation treatment includes but is not limited to the following situations: A)CNLC Ia patients; B) patients with CNLC Ib stage and Child-Pugh score of liver function grade A or better grade B (≤7).\n* The liver area has received external radiotherapy before.\n* Severe pulmonary insufficiency (FEV1\u002FFVC\\&1t; 50% or FEV1\\&1t: 50% expected value or maximum ventilation per minute \\\u003C 50 L\u002Fmin), patients with obvious chronic obstructive pulmonary disease or interstitial pneumonia.\n* Arterial perfusion imaging of technetium \\[99mTc\\] polymerized albumin (99mTc-MAA) showed that the percentage of hepatopulmonary shunt was more than 20%, or the absorbed dose of single lung radiation was more than 30 Gy, or the accumulated absorbed dose of lung radiation was more than 50 Gy.\n* Hepatic arteriography and 99mTc-MAA hepatic artery perfusion imaging showed gastrointestinal shunts, which may not be corrected by vascular interventional techniques.\n* Can't intubate hepatic artery, such as vascular malformation, allergic to contrast agent, allergic to anesthetic, etc.\n* There is a tumor thrombus in the main portal vein.\n* The last anti-tumor treatment (surgery, chemotherapy, immunotherapy, targeted therapy, etc.) is less than 4 weeks before the administration of the experimental drug.\n* Participation in other clinical studies within 4 weeks before the first administration of the study drug.\n* It is expected that any other forms of anti-tumor therapy will be needed during the study.\n* Those who have been vaccinated with live attenuated vaccine within 28 days before the administration of the first study drug or plan to be vaccinated within 60 days after the treatment of the study drug.\n* People with previous history of epilepsy.\n* Patients who have undergone major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks before the first use of the study drug, or need to undergo elective surgery during the trial.\n* Patients who have undergone bone marrow transplantation or solid organ transplantation in the past.\n* Untreated or being treated tuberculosis patients, including but not limited to tuberculosis; Those who have been treated with standardized anti-tuberculosis treatment and confirmed to have been cured by researchers can be included.\n* Patients with active infection of grade ≥2 who need systemic treatment of antibiotics within 2 weeks before the administration of the study drug.\n* Patients who have been diagnosed with immunodeficiency disease and\u002For who have tested positive for human immunodeficiency virus (HIV) at the time of screening.\n* Patients with clinically significant cardiovascular and cerebrovascular diseases within 6 months before the first administration of the study drug, including but not limited to: acute myocardial infarction; Severe\u002Funstable angina pectoris; History of arterial thromboembolism, including but not limited to cerebrovascular accidents; Congestive heart failure \\[new york Heart Association (NYHA) \\> Grade II; Any clinically significant resting ECG rhythm, abnormal conduction or morphology, complete left bundle branch block, degree III cardiac block, degree II cardiac block, and PR interval \\> 250 ms；; The average corrected QT interval (QTCF) obtained by three ECG examinations is \\> 450 msec (C male) or \\> 470 msec (female) (only when the first ECG prompts QTCF to be \\> 450 msec (male) or \\> 470 msec (female), it is necessary to retest and take the average corrected value for three times (corrected according to Fridericia formula); Hypertension beyond the control of antihypertensive drugs (systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg). Other cardiovascular and cerebrovascular diseases that researchers think are not suitable for selection.\n* Have a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid treatment, or any evidence of clinically active ILD.\n* Patients with mental illness that is known to interfere with trial compliance or still need drug control.\n* Pregnant or lactating female patients.\n* Any patient with severe, acute or chronic medical or mental illness or laboratory abnormality who may increase the risk of participating in the study or using the study drugs or may interfere with the interpretation of the study results and who the researcher thinks will not be suitable for participating in the study.\n* According to the investigator's judgment, any other circumstances that prevent the patient from participating in the clinical trial (for safety reasons) or hinder the compliance of the clinical trial procedure (for example, difficulty in venous blood collection).",{"count":52,"type":22},[76],"PHASE1","The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.",[79,28],"Hepatoma",[81,30,82],"unresectable hepatocellular carcinoma","Yttrium-90 Microsphere","2026-01-29",{"date":57,"type":35},{"date":86,"type":35},"2025-08-04",{"date":88,"type":22},"2027-05-31",{"name":90,"class":42},"Suzhou Mednovo Yi Medical Technology Co., Ltd.",8,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":66},"100617111","phase-2-fad-subtype-guided-combination-therapy-for-unresectable-hepatocellular-carcinoma-100617111","NCT07314372","FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","A Prospective Phase II Study of Fatty Acid Degradation (FAD) Subtype-Guided Comprehensive Therapy for Unresectable Hepatocellular Carcinoma","FAD-HCC-001","Inclusion Criteria:\n\n1. Adults ≥18 years of age who voluntarily agree to participate and sign informed consent.\n2. Histologically or cytologically confirmed hepatocellular carcinoma (HCC).\n3. Unresectable or not suitable for curative local therapy, or progression after prior surgery or local therapy.\n4. BCLC stage B or C.\n5. No prior systemic therapy for HCC.\n6. At least one measurable lesion according to RECIST v1.1.\n7. Availability of fresh or archival tumor tissue for FAD subtype testing; if not available at screening, MRI fat fraction may be used temporarily.\n8. Child-Pugh class A or B (≤7 points).\n9. ECOG performance status 0-1.\n10. Adequate organ function, including:\n\n    * ANC ≥1.5 × 10⁹\u002FL\n    * Platelets ≥75 × 10⁹\u002FL\n    * Hemoglobin ≥90 g\u002FL\n    * Albumin ≥30 g\u002FL\n    * Total bilirubin ≤1.5 × ULN\n    * ALT and AST ≤3 × ULN\n    * Serum creatinine ≤1.5 × ULN or creatinine clearance \\>50 mL\u002Fmin\n    * INR ≤1.2 or PT within 2 seconds above ULN\n    * Urine protein \\\u003C2+ or 24-hour urine protein \\\u003C1.0 g\n11. Controlled HBV infection (HBV-DNA \\\u003C2000 IU\u002FmL; if above this level, ≥1 week of antiviral therapy with ≥1-log reduction prior to first dose). HCV-positive individuals must be managed per clinical guidelines.\n12. Life expectancy ≥12 weeks.\n13. Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.\n\nExclusion Criteria:\n\n1. Non-HCC primary liver cancers (e.g., cholangiocarcinoma, combined HCC-CCA).\n2. F3 subtype without liver lesions on imaging.\n3. Clinically significant ascites requiring therapeutic intervention, or uncontrolled pleural\u002Fpericardial effusion.\n4. Interstitial lung disease, pneumonitis requiring steroids, or active pulmonary infection.\n5. Active or history of autoimmune disease requiring systemic treatment (exceptions allowed per protocol, e.g., controlled hypothyroidism).\n6. Recent use (within 2 weeks) of systemic immunosuppressive therapy \\>10 mg\u002Fday prednisone equivalent.\n7. Gastrointestinal bleeding within 6 months, high-risk varices, active ulcers, fistula, perforation, or intra-abdominal abscess.\n8. Known bleeding or clotting disorders; therapeutic anticoagulation not permitted.\n9. Thromboembolic events within 6 months (e.g., stroke, PE).\n10. Significant cardiovascular disease, including NYHA class ≥II heart failure, recent MI (within 1 year), unstable angina, clinically significant arrhythmias, or QTc prolongation.\n11. Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment), or history of hypertensive crisis.\n12. Major vascular disease within 6 months (e.g., arterial thrombosis, aneurysm requiring repair).\n13. Serious non-healing wounds, active ulcers, or fractures.\n14. Inability to swallow oral medication or conditions affecting drug absorption.\n15. Severe infection within 4 weeks, therapeutic antibiotics within 14 days, fever ≥38.5°C within 7 days before enrollment, or WBC \\>15 × 10⁹\u002FL.\n16. Known HIV infection or other causes of immunodeficiency.\n17. Receipt of live attenuated vaccines within 28 days before treatment.\n18. Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results, including substance abuse, severe psychiatric illness, or social factors.",{"count":101,"type":22},86,[103],"PHASE2","This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC). The study uses a metabolic classification system called the fatty acid degradation (FAD) subtype to guide therapy selection. Patients will be assigned to different treatment groups based on their tumor's FAD subtype, determined through RNA-seq analysis of the tumor tissue obtained from liver biopsy.",[28,106,107],"Hepatocellular Carcinoma (HCC)","Liver Cancer Adult",[109,110,111,112,113,114,115,116],"Hepatocellular Carcinoma","Fatty Acid Degradation","Metabolic Subtyping","Precision Medicine","Conversion Therapy","Immunotherapy","Anti-angiogenic Therapy","TACE","2026-01-16",{"date":119,"type":35},"2026-01-20",{"date":121,"type":22},"2026-02-01",{"date":123,"type":22},"2028-12",{"name":125,"class":42},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":66},"100572903","phase-2-sbrt-combined-with-camrelizumab-and-apatinib-for-conversion-therapy-in-patients-with-unresectable-hepatocellular-carcinoma-100572903","NCT06739317","SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.","•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* Signed Informed Consent Form (ICF).\n* Aged 18 years or older.\n* Hepatocellular carcinoma confirmed by histology\u002Fcytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).\n* Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to radical surgery.\n* ECOG Performance Status of 0 or 1.\n* Child-Pugh class of A.\n\nExclusion Criteria:\n\n* Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously.\n* Existence of active autoimmune disease or history of autoimmune disease and may relapse.\n* Patients with innate or acquired immune deficiency (e.g., HIV infection).\n* Known allergies to study drugs or excipients.",{"count":134,"type":22},398,[103,136],"PHASE3","•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.",[28],"2024-12-12",{"date":141,"type":35},"2024-12-18",{"date":143,"type":22},"2025-01-01",{"date":145,"type":22},"2031-06-30",{"name":147,"class":42},"Sun Yat-sen University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":159,"phases":4,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":179},"100513567","observational-sir-spheres-study-for-the-treatment-of-unresectable-liver-tumors-sirtain-registry-100513567","NCT05967143","Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)","Observational Study to Assess Real-World Outcomes in Patients With Unresectable Liver Tumors Initiating Treatment With SIR-Spheres (Y-90 Resin Microspheres) (SIRtain Registry)","SIRtain","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed diagnosis of:\n* Unresectable hepatocellular carcinoma (HCC) Or\n* Unresectable liver metastases from colorectal cancer (mCRC) refractory to or intolerant to chemotherapy\n* Identified as a candidate for SIR-Spheres treatment as deemed appropriate during the normal course of practice\n* Planned to receive SIR-Spheres treatment to the liver for the first time\n* Provision of signed patient informed consent\n\nExclusion Criteria:\n\n* Prior radiation treatment to the liver\n\nCaveat:\n\nSequential selective internal radiation therapy (SIRT) treatment is allowed\n\n* Patients participating in any interventional clinical trial with an investigational product, device, or procedure\n* Need for surrogate consent. Patients who are not able to consent on behalf of themselves are not eligible.",{"count":157,"type":22},845,"2 Years","OBSERVATIONAL","This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres",[28,162],"Liver Metastases From Colorectal Cancer (mCRC)",[164,165,166,167,168],"Liver metastases from colorectal cancer (mCRC)","Unresectable Hepatocellular carcinoma (HCC)","SIR-Spheres microspheres","Y-90 resin microspheres","SIRT","2024-11-26",{"date":171,"type":35},"2024-11-27",{"date":173,"type":35},"2023-06-19",{"date":175,"type":22},"2029-06",{"name":177,"class":178},"Sirtex Medical","INDUSTRY",9]